2024
S1497 Prevalence and Impact of Zinc Deficiency on Clinical Outcomes in Inflammatory Bowel Disease
Almuhaya H, Alsalamah R, Sallam A, Alonazy A, AlAwwad A, Mohamed G, Almutairdi A, Attamimi M, Al-Bawardy B. S1497 Prevalence and Impact of Zinc Deficiency on Clinical Outcomes in Inflammatory Bowel Disease. The American Journal Of Gastroenterology 2024, 119: s1083-s1084. DOI: 10.14309/01.ajg.0001035356.00119.f9.Peer-Reviewed Original ResearchS1498 Prevalence and Outcomes of Active and Latent Tuberculosis Among Patients With Inflammatory Bowel Disease (IBD) in an Endemic Region
Alayed M, Alrasheed A, Alenezi M, Binsalmah I, Almutairdi A, Attamimi M, Al-Bawardy B. S1498 Prevalence and Outcomes of Active and Latent Tuberculosis Among Patients With Inflammatory Bowel Disease (IBD) in an Endemic Region. The American Journal Of Gastroenterology 2024, 119: s1084-s1085. DOI: 10.14309/01.ajg.0001035360.73644.fd.Peer-Reviewed Original ResearchS1066 Outcomes of Isolated Recurrent, Persistent Complex Perianal Fistulas Without Luminal Crohn’s Disease: A Case Series of 24 Patients
Fiske H, Tse C, Al-Bawardy B, Magavi P, Konijeti G, Mao E, Fine S, Parian A, Lazarev M, Shah S. S1066 Outcomes of Isolated Recurrent, Persistent Complex Perianal Fistulas Without Luminal Crohn’s Disease: A Case Series of 24 Patients. The American Journal Of Gastroenterology 2024, 119: s752-s756. DOI: 10.14309/01.ajg.0001033632.76152.4b.Peer-Reviewed Original ResearchS1165 Prevalence and Risk Factors for Ulcerative Colitis Flares After Colonoscopy
Khan F, Chung S, Kadhim B, Ameyaw P, Fetene J, Dominguez-Diaz A, Al-Bawardy B, Levy A, Proctor D, Gaidos J. S1165 Prevalence and Risk Factors for Ulcerative Colitis Flares After Colonoscopy. The American Journal Of Gastroenterology 2024, 119: s827-s828. DOI: 10.14309/01.ajg.0001034028.79665.88.Peer-Reviewed Original ResearchRisankizumab for Ulcerative Colitis
Louis E, Schreiber S, Panaccione R, Bossuyt P, Biedermann L, Colombel J, Parkes G, Peyrin-Biroulet L, D’Haens G, Hisamatsu T, Siegmund B, Wu K, Boland B, Melmed G, Armuzzi A, Levine P, Kalabic J, Chen S, Cheng L, Shu L, Duan W, Pivorunas V, Sanchez Gonzalez Y, D’Cunha R, Neimark E, Wallace K, Atreya R, Ferrante M, Loftus E, Balderramo D, Goncalves S, Lasa J, Novillo A, Ruffinengo O, Heeren S, Reinisch W, Baert F, Bossuyt P, Colard A, Dewit O, Ferrante M, Franchimont D, Louis E, Rahier J, Francesconi C, Kaiser Junior R, Parra R, Sassaki L, Penchev P, Stanchev D, Atkinson K, Beaton M, Bessissow T, Greenbloom S, Lachance J, Lim A, Panaccione R, Samson J, Shulman S, Siffledeen J, Alfaro I, Valenzuela C, Walsen G, An P, Cao Q, Chen Y, Chen Y, Gao X, Hou X, Hu N, Li Y, Liu F, Liu M, Lungen L, Ran Z, Tang T, Wang X, Yang S, Zhan Q, Zhang G, Zhang H, Zhang J, Zhang X, Zhong J, Zou X, Alvarez E, Ricaurte J, Borzan V, Krznaric Z, Puljiz Z, Bortlik M, Svoboda P, Ulbrych J, Vanasek T, Kjeldsen J, Munck L, Poulsen A, Ali E, Salem O, Sawah H, Waked I, Altwegg R, FLAMANT M, Fumery M, Hebuterne X, Laharie D, Peyrin-Biroulet L, Roblin X, Treton X, Atreya R, Deppe H, Hasselblatt P, Kandulski A, Klaus J, Krause T, Kucharzik T, Mertens J, Mross M, Naumann A, Reindl W, Schiefke I, Schreiber S, Schubert S, Siegmund B, Sturm A, Bamias G, Koutroubakis I, Manolakopoulos S, Mantzaris G, Tzouvala M, Viazis N, Avni-Biron I, Goldin E, Katz L, Lahat-Zok A, Segal A, Ardizzone S, Armuzzi A, Cicala M, Colecchia A, Cosintino R, Gasbarrini A, Geccherle A, Giannini E, Gionchetti P, Luzza F, Monteleone G, Privitera A, Saibeni S, Vangeli M, Abe Y, Aoyama N, Asonuma K, Endo Y, Esaki M, Fujii T, Fukuda K, Hirai F, Hisanaga Y, Horiki N, Iguchi M, Ishigami K, Ishiguro Y, Ito H, Kakuta Y, Kamikozuru K, Kato J, Kawanishi T, Kobayashi T, Kuge H, Maemoto A, Masuda T, Matsuoka K, Matsushima K, Matsushima M, Motoya S, Nakai K, Nakajima K, Nakamura M, Nishida A, Nishikawa T, Nishimata N, Ochiai T, Ohmiya N, Ohnishi Y, Oka S, Ozeki K, Saito D, Saruta M, Sasaki M, Shimizu M, Sugimoto K, Sujino T, Suzuki T, Takatori H, Takatsu N, Takedatsu H, Takeuchi K, Tanaka H, Tokito S, Endo T, Toyokawa T, Uenoyama Y, Yamamoto T, Yamamoto T, Yasuda H, Yokoyama K, Derovs A, Pukitis A, Jonaitis L, Kazenaite E, Pinzon Te L, D'Haens G, Lutgens M, Brooker J, Gearry R, Griffiths B, Inns S, Schultz M, Eszyk J, Kierkus J, Kleczkowski D, Kopon A, Petryka R, Regula J, Romanczyk T, Rydzewska-Wyszkowska G, Sikorski P, Talarek M, Cerqueira R, Goncalves T, Lopes S, Ministro P, Portela F, Tavares H, Diculescu M, Goldis A, Seicean A, Agafina A, Edin A, Gerasimova E, Gettueva M, Kashnikov V, Pirmagomedov A, Rafalskiy V, Sharapova K, Smolyarchuk E, Varganova D, Grgov S, Jovanovic I, Svorcan P, Tarabar D, Ling K, Balaz J, Durina J, Gregus M, Laclav M, Drobne D, Deetlefs E, Peter J, Rajabally M, Rosa J, van Zyl J, Wright J, Cheon J, Jang B, Kim J, Kang S, Kim D, Kim T, Kim Y, Lee J, Lee K, Park D, Song G, Arguelles Arias F, Castro Laria L, Echarri Piudo A, Garcia Lopez S, Hernandez Ramirez V, Martin Arranz M, Varela Trastoy P, Vera Mendoza M, Lordal M, Biedermann L, Misselwitz B, Chang C, Chou J, Kuo C, Lin C, Tu C, Alkim H, Erzin Y, Soykan I, Kravchenko T, Tsarynna N, Vyshyvanyuk V, Ahmad T, Cummings F, Kapur K, Kaser A, Kent A, Parkes G, Patel K, Speight R, Steel A, Aberra F, Aguilar H, Al Bawardy B, Ananthakrishnan A, Barnes M, Beck K, Berkelhammer C, Boland B, Bullock J, Chiplunker A, Dalal R, Dalal S, Delgado B, DiGiovanna M, DuVall G, Freedland C, Friedenberg K, Gaidos J, Ginsburg P, Hassanein T, Higgins P, Hong J, Hou J, Huilgol V, Inamdar N, Kapur S, Kerman D, Levine H, Lodhia N, Loftus E, Mayoral J, McNeil D, Melmed G, Mushahwar A, Ojeas H, Patel B, Phillips R, Pouzar J, Sarles H, Schock J, Sedghi S, Shah N, Siddiqui J, Stokesberry D, Su L, Swaminath A, Verma D, Weber J, Younes Z, Zisman T. Risankizumab for Ulcerative Colitis. JAMA 2024, 332: 881-897. PMID: 39037800, PMCID: PMC11264075, DOI: 10.1001/jama.2024.12414.Peer-Reviewed Original ResearchClinical remission rateActive ulcerative colitisRemission rateUlcerative colitisInduction trialsMaintenance trialsClinical centersPhase 3 randomized clinical trialModerately to severely active ulcerative colitisSeverely active ulcerative colitisSafety of risankizumabTreatment of ulcerative colitisHistory of intoleranceMaintenance therapyClinical remissionClinical responseResponse to 1Intravenous treatmentRisankizumabAdverse event signalsConventional therapySubcutaneous treatmentFollow-upPlaceboAdvanced therapiesSaudi consensus guidance for the diagnosis and management of inflammatory bowel disease in children and adolescents.
Saadah O, AlAmeel T, Al Sarkhy A, Hasosah M, Al-Hussaini A, Almadi M, Al-Bawardy B, Altuwaijri T, AlEdreesi M, Bakkari S, Alharbi O, Azzam N, Almutairdi A, Alenzi K, Al-Omari B, Almudaiheem H, Al-Jedai A, Mosli M. Saudi consensus guidance for the diagnosis and management of inflammatory bowel disease in children and adolescents. Saudi Journal Of Gastroenterology 2024 PMID: 39215473, DOI: 10.4103/sjg.sjg_171_24.Peer-Reviewed Original ResearchInflammatory bowel diseaseSociety of Clinical PharmacyAdolescents aged 6Saudi Ministry of HealthMinistry of HealthManagement of inflammatory bowel diseaseSaudi Gastroenterology AssociationSaudi Society of Clinical PharmacyPediatric inflammatory bowel diseaseClinical pharmacyGastroenterological AssociationAged 6Bowel diseaseSaudi MinistryGuideline statementsManagement of pediatric inflammatory bowel diseaseSaudi childrenConsensus guidanceAdolescentsChildrenSaudiSaudi societyHealthPharmacyDiagnosisInflammatory bowel disease training assessment of gastroenterology fellows in Saudi Arabia.
AlDhneem H, AlMutairdi A, Attamimi M, Mosli M, AlAmeel T, Al-Bawardy B. Inflammatory bowel disease training assessment of gastroenterology fellows in Saudi Arabia. Saudi Journal Of Gastroenterology 2024, 30: 260-265. PMID: 38841910, PMCID: PMC11379256, DOI: 10.4103/sjg.sjg_19_24.Peer-Reviewed Original ResearchInflammatory bowel diseaseGI fellowsElderly/frail patientsAssociated with higher confidenceExternal rotationInflammatory bowel disease knowledgePreventive health servicesMulticenter survey studyManagement of inflammatory bowel diseaseInflammatory bowel disease managementGastroenterology fellowsHealth servicesSaudi ArabiaFellows' confidenceDidactic sessionsMethods of trainingExtraintestinal manifestationsCounseling patientsIBD patientsBowel diseaseIBD managementPatientsPreference learning methodLow confidenceConfidenceA Rare Cause of Acute Pancreatitis
Alghaythi S, Al-Bawardy B, Almuhaidb A. A Rare Cause of Acute Pancreatitis. Clinical Gastroenterology And Hepatology 2024, 22: a27-a28. PMID: 38768674, DOI: 10.1016/j.cgh.2024.04.040.Peer-Reviewed Original ResearchRates, Predictors, and Outcomes of Ustekinumab Dose Escalation in Inflammatory Bowel Disease.
Petrov J, Al-Bawardy B, Alzahrani R, Mohamed G, Fine S. Rates, Predictors, and Outcomes of Ustekinumab Dose Escalation in Inflammatory Bowel Disease. Journal Of Clinical Gastroenterology 2024 PMID: 38595134, DOI: 10.1097/mcg.0000000000002003.Peer-Reviewed Original ResearchUstekinumab dose escalationDose-escalation groupInflammatory bowel diseaseDose escalationC-reactive proteinEndoscopic healingEscalation groupClinical remissionNormalization of C-reactive proteinSteroid-free clinical remissionBowel diseaseSerum C-reactive proteinNormalization of serum C-reactive proteinMaintenance of remissionReal-world cohortProportion of patientsUstekinumab doseMean hemoglobinBaseline albuminRetrospective studyUstekinumabMale sexMultivariate analysisPrimary outcomeSecondary outcomesClinical Decision Making in Inflammatory Bowel Disease Mimics: Practice Management from Inflammatory Bowel Disease LIVE
Fiske H, Ward C, Shah S, Holubar S, Al-Bawardy B, Barnes E, Binion D, Bohm M, Brand M, Clarke K, Cohen B, Cross R, Dueker J, Engels M, Farraye F, Fine S, Forster E, Gaidos J, Ginsburg P, Goyal A, Hanson J, Herfath H, Hull T, Kelly C, Lazarev M, Levy L, Melia J, Philpott J, Qazi T, Siegel C, Watson A, Wexner S, Williams E, Regueiro M. Clinical Decision Making in Inflammatory Bowel Disease Mimics: Practice Management from Inflammatory Bowel Disease LIVE. Crohn's & Colitis 360 2024, 6: otae022. PMID: 38720935, PMCID: PMC11078036, DOI: 10.1093/crocol/otae022.Peer-Reviewed Original ResearchInflammatory bowel diseaseReview of patient historyPresentation of inflammatory bowel diseaseInflammatory bowel disease patientsTreated with biologicsCost of patient careClinical management implicationsReassessment of treatmentIBD specialistsClinical responseMedication-inducedIBD patientsPrescribed steroidsPatient careEndoscopic biopsyTherapeutic workupMultidisciplinary managementIBD casesBalloon enteroscopyAdverse eventsDifferential diagnosisDisease mimicsDiverse presentationsPatient historyBowel diseaseLonger Colonoscopy Withdrawal Time Is Associated With the Detection of Visible Dysplasia in Patients With Inflammatory Bowel Disease
McMillan C, Li D, Mohamed G, Alsadoun D, Almohsen L, Gaidos J, Proctor D, Al-Bawardy B. Longer Colonoscopy Withdrawal Time Is Associated With the Detection of Visible Dysplasia in Patients With Inflammatory Bowel Disease. Crohn's & Colitis 360 2024, 6: otae020. PMID: 38585555, PMCID: PMC10998460, DOI: 10.1093/crocol/otae020.Peer-Reviewed Original ResearchColonoscopy withdrawal timeHigh-definition white light colonoscopyInflammatory bowel diseaseWhite light colonoscopyVisible dysplasiaBowel diseasePersonal historyWithdrawal timeAssociated with detectionEndoscopic healingAdenoma detectionDysplasia detectionDysplasia groupRetrospective studyAdult patientsInvisible dysplasiaColonoscopyPrimary outcomeDysplasiaMultivariate analysisPatientsIncreasing ageGeneral populationMinutesDiseaseImpact of COVID-19 Treatment on Real-World Outcomes in Inflammatory Bowel Disease
Sahyoun L, Fetene J, McMillan C, Protiva P, Al Bawardy B, Gaidos J, Proctor D. Impact of COVID-19 Treatment on Real-World Outcomes in Inflammatory Bowel Disease. Digestive Diseases And Sciences 2024, 69: 1654-1660. PMID: 38466459, DOI: 10.1007/s10620-024-08355-3.Peer-Reviewed Original ResearchSevere COVID-19 infectionInflammatory bowel diseaseCOVID-19 infectionIBD flareIBD therapyCOVID-19 treatmentSingle-center retrospective study of adult patientsMethodsA single-center retrospective studyAdvanced therapiesRetrospective study of adult patientsBowel diseaseStudy of adult patientsInflammatory bowel disease therapyDevelopment of severe COVID-19 infectionSevere COVID-19Acute COVID-19Corticosteroid useNo significant differenceNo therapyAdult patientsSupplemental oxygenPrimary outcomeSecondary outcomesTherapyCorticosteroidsEpstein-Barr virus seroprevalence among inflammatory bowel disease patients in Saudi Arabia
Al-Bawardy B, Alfadley A, Almousallam M, AlShathri S, Aboueissa M, Alsulaiman A, Attamimi M, AlMutairdi A. Epstein-Barr virus seroprevalence among inflammatory bowel disease patients in Saudi Arabia. Saudi Journal Of Gastroenterology 2024, 30: 168-172. PMID: 38358251, PMCID: PMC11198918, DOI: 10.4103/sjg.sjg_380_23.Peer-Reviewed Original ResearchSeroprevalence of EBVEpstein-Barr virusInflammatory bowel diseaseYears of ageEBV seroprevalenceEpstein-Barr virus statusCohort of IBD patientsDiagnosis of inflammatory bowel diseaseInflammatory bowel disease patientsRetrospective chart reviewFollow-up timeRate of seroconversionNon-exposureEBV seroconversionThiopurine therapyEBV-seropositiveNegative patientsTertiary centerIBD patientsPrimary outcomeSecondary outcomesBowel diseasePatientsVirus seroprevalenceDisease patientsUstekinumab Drug Levels and Outcomes in Inflammatory Bowel Disease.
Petrov J, Fine S, Alzahrani R, Mohamed G, Al-Bawardy B. Ustekinumab Drug Levels and Outcomes in Inflammatory Bowel Disease. Journal Of Clinical Gastroenterology 2024 PMID: 38300529, DOI: 10.1097/mcg.0000000000001978.Peer-Reviewed Original ResearchArea under the curveInflammatory bowel diseaseEndoscopic healingTrough levelsBowel diseaseAssociated with favorable outcomesUstekinumab trough levelsHighest area under the curveCohort of patientsTherapeutic drug monitoringClinical remissionCombination therapyMedian ageCRP normalizationRetrospective studyDrug levelsFavorable outcomeUstekinumabDrug monitoringPrimary outcomeSecondary outcomesCRPPatientsOutcomesHealingInflammatory bowel disease burden in the Middle East and North Africa Region: a comprehensive analysis of incidence, prevalence, and mortality from 1990-2019
Alsakarneh S, Ahmed M, Jaber F, Abuassi M, Mourad F, Francis F, Barada K, Tfayli R, Al-Bawardy B, Farraye F, Hashash J. Inflammatory bowel disease burden in the Middle East and North Africa Region: a comprehensive analysis of incidence, prevalence, and mortality from 1990-2019. Annals Of Gastroenterology 2024, 37: 527-535. PMID: 39238799, PMCID: PMC11372542, DOI: 10.20524/aog.2024.0909.Peer-Reviewed Original ResearchIBD burdenGlobal Burden of DiseaseDisability-adjusted life yearsMiddle East and North Africa regionPrevalence rates of inflammatory bowel diseaseAge-standardized mortality ratesRates of inflammatory bowel diseaseEpidemiology of inflammatory bowel diseaseInflammatory bowel disease incidenceMortality rateInflammatory bowel diseaseSex-specific trendsBurden of diseaseAnalysis of incidentsGlobal burdenMiddle East and North AfricaIncidence rateLife yearsDisease burdenPrevalence ratesStudy databasePrevalenceGeographic variationObjective dataBurden
2023
Saudi consensus guidance for the management of inflammatory bowel disease during pregnancy.
Azzam N, Almutairdi A, Almudaiheem H, AlAmeel T, Bakkari S, Alharbi O, Alenzi K, AlMolaiki M, Al-Omari B, Albarakati R, Al-Jedai A, Saadah O, Almadi M, Al-Bawardy B, Mosli M. Saudi consensus guidance for the management of inflammatory bowel disease during pregnancy. Saudi Journal Of Gastroenterology 2023, 30 PMID: 38099556, PMCID: PMC11379253, DOI: 10.4103/sjg.sjg_318_23.Peer-Reviewed Original ResearchInflammatory bowel diseaseManagement of IBDPregnant womenBowel diseaseClear evidence-based recommendationsSubset of patientsClinical care pathwayExpert opinion recommendationsOptimal patient managementEvidence-based recommendationsMultidisciplinary working groupCare pathwayClinical pharmacologyPatient managementPatient basisConsensus guidanceMultidisciplinary teamSaudi MinistryWomenPatientsDiseaseConcise guidelinesWorking GroupLiterature reviewManagementTherapeutic drug monitoring of ustekinumab and vedolizumab in inflammatory bowel disease: worth the draw?
Chaar A, Atiyat R, Al-Bawardy B. Therapeutic drug monitoring of ustekinumab and vedolizumab in inflammatory bowel disease: worth the draw? Digestive Medicine Research 2023, 0: 0-0. DOI: 10.21037/dmr-22-80.Peer-Reviewed Original ResearchScRNA-seq defines dynamic T-cell subsets in longitudinal colon and peripheral blood samples in immune checkpoint inhibitor-induced colitis
Mann J, Lucca L, Austin M, Merkin R, Robert M, Al Bawardy B, Raddassi K, Aizenbud L, Joshi N, Hafler D, Abraham C, Herold K, Kluger H. ScRNA-seq defines dynamic T-cell subsets in longitudinal colon and peripheral blood samples in immune checkpoint inhibitor-induced colitis. Journal For ImmunoTherapy Of Cancer 2023, 11: e007358. PMID: 37586769, PMCID: PMC10432652, DOI: 10.1136/jitc-2023-007358.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsT cell subsetsCheckpoint inhibitorsImmune environmentImmune checkpoint inhibitor-induced colitisCheckpoint inhibitor-induced colitisPeripheral immune environmentsStages of colitisTreatment of colitisMerkel cell carcinomaT cell populationsPeripheral blood samplesCourse of progressionT cell receptorMultiple tumor typesAlternative cancer therapyCommon toxicitiesICI colitisTreatment discontinuationAdverse eventsBiologic therapyImmune suppressionCell carcinomaColitisBlood samplesEmerging Therapies for Ulcerative Colitis: Updates from Recent Clinical Trials
AlAmeel T, AlMutairdi A, Al-Bawardy B. Emerging Therapies for Ulcerative Colitis: Updates from Recent Clinical Trials. Clinical And Experimental Gastroenterology 2023, 16: 147-167. PMID: 37609124, PMCID: PMC10441644, DOI: 10.2147/ceg.s375969.Peer-Reviewed Original ResearchManagement of UCToll-like receptor 9Ulcerative colitisAdvanced therapiesSubcutaneous tumor necrosis factor (TNF) inhibitorsPhosphodiesterase 4 inhibitor apremilastTumor necrosis factor inhibitorsInnovative clinical trial designsNecrosis factor inhibitorsRecent clinical trialsProgressive inflammatory disorderClinical trial designFurther drug developmentRemission rateBiologic agentsFactor inhibitorsInflammatory disordersTherapeutic armamentariumReceptor 9Clinical trialsAvailable agentsTrial designTherapyColitisDrug developmentOutcomes of Infliximab-Treated inflammatory bowel disease patients undergoing therapeutic drug monitoring with two different assays
Al-Bawardy B, Jenkins S, Snyder M, Frinack J, Ladwig P, Loftus E, Willrich M. Outcomes of Infliximab-Treated inflammatory bowel disease patients undergoing therapeutic drug monitoring with two different assays. Clinical Biochemistry 2023, 119: 110618. PMID: 37507083, DOI: 10.1016/j.clinbiochem.2023.110618.Peer-Reviewed Original ResearchConceptsInflammatory bowel disease patientsBowel disease patientsEndoscopic healingClinical remissionDisease patientsMcg/Normal serum C-reactive proteinDrug monitoringSerum C-reactive proteinLC-MS/MSInfliximab drug levelsFavorable clinical outcomeC-reactive proteinTherapeutic drug monitoringIBD patientsNormal CRPClinical outcomesDrug levelsPatientsECLIARemissionDifferent assaysOutcomesMcgAssays